Сравнение

Semaglutid vs. VK2735

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

910463-68-2

нет данных

Молекулярная масса

4113.6 g/mol

нет данных

Период полувыведения

165 h

нет данных

Последовательность

modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-Linker

нет данных

Механизм действия

Semaglutid

Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Semaglutid	VK2735
Швейцария	Рецептурный	—
Германия	Рецептурный	Не одобрено
США	Рецептурный	Не одобрено

Полные записи

Frequently asked questions

What is the difference between Semaglutid and VK2735?: Semaglutid is classified as "Метаболизм", while VK2735 is classified as "Метаболизм". Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Semaglutid or VK2735?: The highest available evidence level is "РКИ на людях" for Semaglutid and "РКИ на людях" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Semaglutid and VK2735 in Germany and the United States?: Германия: Semaglutid — Рецептурный, VK2735 — Не одобрено. США: Semaglutid — Рецептурный, VK2735 — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

Semaglutid

VK2735

Швейцария

Рецептурный

—

Германия

Рецептурный

Не одобрено

США

Рецептурный

Не одобрено

Frequently asked questions

What is the difference between Semaglutid and VK2735?

Semaglutid is classified as "Метаболизм", while VK2735 is classified as "Метаболизм". Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Semaglutid or VK2735?

The highest available evidence level is "РКИ на людях" for Semaglutid and "РКИ на людях" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Semaglutid and VK2735 in Germany and the United States?

Германия: Semaglutid — Рецептурный, VK2735 — Не одобрено. США: Semaglutid — Рецептурный, VK2735 — Не одобрено. These are factual summaries with source and review date on the individual pages.